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Patients with severe, painful injuries and illnesses treated in the emergency department are commonly administered opioid
medications.Intravenousadministrationprovidesthemostrapidonsetofpainreliefandisreadilytitrated.Fentanyl,administered
intravenously, is well documented as an eﬀective medication for pain management in the emergency department. It is preferred in
many settings due to its minimal hemodynamic eﬀects, as compared to other commonly used opioids. However, not all patients
require intravenous access. These patients are given orally administered pain medications. The oral route is eﬀective at minimizing
pain but has a much slower onset of action when compared to the intravenous route. As an alternative to the slower onset of action
seen with oral opioids, this paper discusses the use of fentanyl buccal tablet for pain management in the emergency department.
Fentanyl buccal tablets are readily absorbed, with a bioavailability of approximately 65%, and have a more rapid onset of action
than achieved with traditional oral opioids used in the emergency department.
1.Introduction
The relief of acute pain secondary to minor orthopedic in-
juries is often delayed and inadequate in the emergency de-
partment [1, 2]. This issue, referred to as oligoanalgesia, has
been demonstrated in both the USA and abroad. The fre-
quent delay in analgesia delivery is best illustrated by a UK
study that revealed a 3-hour 56-minute mean time to re-
ceipt of analgesia for patients with moderate pain. On aver-
age, there was a 1-hour 8-minute delay between analgesia
prescription and administration [2]. In addition, for cases in
which oral analgesics are prescribed, the relief of pain is even
further delayed by their relatively slow onset.
OralNSAIDSandopioidsarecommonlyusedinpatients
with minor orthopedic injuries, but with several disadvan-
tages. The many risks of NSAIDs have been well described,
and NSAID therapy has consequences speciﬁc to orthopedic
injuries (nonunion) [3]. Although oral opioids do not have
the same risk proﬁle as NSAIDs, both of these options have a
much slower onset than intravenous opioids.
Intravenousopioidsareoftenchosenfortheirrapidonset
among other beneﬁts. While intravenous access is typically
easy to obtain in the emergency department, it may be oth-
erwise unnecessary in many patients with minor orthopedic
injuries. In these instances, obtaining intravenous access not
only exposes the patient to increased discomfort but further
delays medication administration.
The time to pain relief in patients with minor orthopedic
injuries could be signiﬁcantly reduced by an alternative ana-
lgesic. This alternative would ideally have a rapid onset and
be administered in a simple fashion via a nonparenteral
route. With these goals in mind, the authors propose an oﬀ-
label indication for fentanyl buccal tablet (FBT) as a novel
form of analgesia in the emergency department for patients
with isolated minor orthopedic injuries.
2. Transbuccal FentanylPharmacokinetics
andPharmacodynamics [4]
Fentanyl is an intravenous analgesic commonly used in the
emergency department (ED). The intravenous dosage form
exhibits linear pharmacokinetics. Another dosage form of
fentanyl, the FBT, also reﬂects linear pharmacokinetics, in2 Pain Research and Treatment
a nearly dose-proportional manner, over the 100mcg to
800mcgdoserange.FBTisabsorbedreadilywithabioavaila-
bility of 65%. The buccal mucosa is the initial location
of absorption, with peak plasma concentrations occurring
within an hour of administration. Transmucosal absorption
accounts for approximately 50% of the total administered
dose. Swallowing contributes to the other 50% of the total
doseabsorption,overaprolongedperiod,inthegastrointest-
inal tract. As a comparison, FBT exhibits an approximately
28% greater bioavailability over the oral transmucosal fen-
tanyl citrate (OTFC; “lozenges”), FBT 65% and OTFC 47%.
This diﬀerence is likely due to the FBT exhibiting appro-
ximately 55% more of the total dose absorbed transmu-
cosally than with OTFC. This diﬀerence also results in the
inability to substitute at an equal dose these two transmu-
cosal forms of fentanyl. In a study comparing OTFC with
oral oxycodone for pediatric outpatient wound care, the in-
vestigators found that transmucosal administration of opi-
oids produced similar sedation and analgesia to other opioid
delivery methods [5]. Increased bioavailability, more rapid
onset of analgesia, and faster time to peak plasma levels are
also seen with the transmucosal opioid delivery systems. The
transmucosalfentanylsdisplayanonsetofanalgesiaactionin
5t o1 5m i n u t e sw i t hap e a ke ﬀe c ts e e ni n1 5t o3 0m i n u t e s .
The fentanyl systemic exposure is not apparently aﬀected by
the length of time an FBT tablet takes to disintegrate fully
in the buccal area after administration. When the FBT is
compared to oxycodone immediate release (IR) for break-
through pain in chronic pain patients the primary measure
of eﬃcacy, the level of pain intensity diﬀerence at 15 mi-
nutes, signiﬁcantly favored FBT over the oxycodone [6]. The
adverse events reported in this study were typical of opioid
pain medication and were similar between the 2 treatment
groups, FBT and oxycodone IR.
Fentanyl, including transmucosal forms, is highly lipo-
philic. It is also greatly bound, 80–85%, to plasma protein.
Alpha-1-acid glycoprotein is the main binding protein, but
fentanyl also binds to albumin and lipoproteins. The mean
steady-state volume of distribution is 25.4L/kg. Fentanyl
is metabolized by the cytochrome P450 3A4 system in the
liver to norfentanyl, a pharmacologically inactive metabolite.
Inactive metabolites account for more than 90% of the eli-
mination of fentanyl, with less than 7% of the total dose ad-
ministered, excreted unchanged in the urine.
3. ExistingEvidencefor FentanylBuccal Tablet
Intravenous fentanyl is frequently used in acute care and
has a proven track record. A rapid onset, short duration of
action, good response to opiate antagonists, and minimal
hemodynamic eﬀects make fentanyl a very desirable option
in the acute care setting [7, 8]. While the intravenous form
is commonly used, alternative administration routes include
the fentanyl buccal tablet, the fentanyl buccal soluble ﬁlm,
oral transmucosal fentanyl (lozenges), intranasal fentanyl,
and nebulized fentanyl.
Although oral transmucosal fentanyl has been frequently
used in the emergency department for pediatric procedural
sedation, the transbuccal forms have been shown to have
both greater bioavailability and a more rapid onset [9–11].
Intranasal and nebulized fentanyl are also viable options but
intranasal fentanyl has primarily been studied in pediatrics
and nebulized fentanyl lacks the simple method of delivery
that FBT has to oﬀer [12, 13]. In contrast, the fentanyl buc-
cal tablet is simple to administer while still providing a rapid
onset.Inhealthyvolunteers,asingle400mcgdoseofFBThas
been shown to have a mean time to maximum plasma con-
centration of 52.2 minutes [14]. To put this in perspective, a
single 5mg swallowed dose of immediate release oxycodone
has a mean time to maximum plasma concentration of 1.4
hours (a diﬀerence of 31.8 minutes) [15].
Use of the fentanyl buccal tablet has traditionally been
reserved for breakthrough pain in cancer patients. This is the
only Federal Drug Administration (FDA) approved indica-
tion for this dosage form of fentanyl. This population has
been well studied, and transbuccal fentanyl has been shown
to have a more rapid onset when compared to immediate
release oxycodone in these patients [6]. Transbuccal fentanyl
can be used in the emergency department to ﬁll the pre-
viously described void between oral and intravenous anal-
gesia. Although current emergency department research fo-
cusesonthefentanylbuccaltabletform,itshouldbeacknow-
ledged that the fentanyl buccal soluble ﬁlm may also be an
excellent choice [11, 16].
Currently, the literature regarding fentanyl buccal tablet
use in the ED setting consists of the Fentanyl Administered
Intraorally for Rapid Treatment of Orthopedic Pain in the
ED (FAIRTOP) trial [17]. In this double-blind randomized
controlled trial, 60 participants were given either a fentanyl
buccal tablet (100mcg) with a swallowed placebo or an oxy-
codone/acetaminophen (5/325mg) tablet swallowed with
a nonopioid transbuccal “placebo.” A lansoprazole 15mg
transbuccal tablet was used as the nonopioid transbuccal
“placebo.” With a two-unit drop in numeric pain scale (0
to 10) as the primary endpoint, the median time to end-
point was 10 minutes in the fentanyl buccal tablet group
versus 35 minutes in the oxycodone/acetaminophen group
(P = .0001). The reported adverse eﬀects were minimal in
this study. There was one episode of vomiting in the oxy-
codone/acetaminophen group and 13% of patients overall
experienced nausea (27% of the oxycodone/acetaminophen
group and 0% of the fentanyl buccal tablet group, P = .005).
Only one case of nausea was described as being greater than
slight nausea. In addition, some subjects described feelings
such as “woozy” or “dizzy,” but this had an approximately
equal frequency between the groups and is not unusual with
the use of narcotics. Vital signs were monitored and no other
adverse eﬀects were noted.
The investigators of the FAIRTOP trial acknowledged
both its limitations and the need for further investigation.
First, while the sample size was large enough to demonstrate
a signiﬁcant diﬀerence in time to primary endpoint, reduc-
tion in pain level, the low sample size provided limited infor-
mation concerning side eﬀects. Secondly, there was some
question as to whether an equianalgesic dose of fentanyl and
oxycodone/acetaminophen was used. Lastly, although there
was no known source for selection bias, it is a concern due to
convenience sampling. Despite these limitations, the resultsPain Research and Treatment 3
are very promising. That being said, with the limited data
in the published literature, further investigation is needed to
more clearly deﬁne both safety and eﬃcacy and to guide de-
cision making prior to widespread transbuccal fentanyl use
in the ED setting.
4.FutureResearch
The FAIRTOP II trial aims to further deﬁne the beneﬁts of
FBT. As a secondary objective, this new trial intends to pro-
vide more information regarding side eﬀect rates and a com-
parison of the time to onset between a 200mcg dose of FBT
to 2, oxycodone/APAP 5mg/325mg tablets. There is a need
for future studies to examine the eﬀects of doses greater than
100mcg and 200mcg in the prehospital and ED population,
for patients experiencing severe pain.
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